Importance: Congenital chylothorax is a rare condition with pulmonary and multiorgan system effects, for which there are no standardized treatment recommendations. Collective review of known cases offers some conclusions and suggestions for treatment.
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| Case 1
A female infant delivered vaginally after induction at 31 6/7 weeks gestational age (GA) and birth weight (BW) of 2190 g was diagnosed prenatally with bilateral chylothoraces and early hydrops fetalis on a 21-week ultrasound. In utero, thoracentesis was performed twice and pleurodesis was attempted. Delivery was induced due to maternal chorioamnionitis and prolonged rupture of membranes. Pleural effusions persisted postnatally. The patient was intubated in the delivery room for lack of spontaneous respirations. The patient developed respiratory failure, which required the use of high-frequency ventilation on day of life (DOL) 1. Bilateral chest tubes were in place from DOL 1 to DOL 8. The patient's course was complicated by pulmonary hypertension (PH), diagnosed by elevated right ventricular pressure (RVP) on echocardiogram on DOL 2, and a patent ductus arteriosus (PDA). Dopamine was initiated for hypotension, and inhaled nitric oxide was used to treat PH from DOL 3 through 6. The PDA closed spontaneously during the first 6 days of life. PH improved, although still present, on echocardiogram on DOL 6 when inhaled nitric oxide was discontinued. Reduced long-chain fatty acid (LCFA) formula was started on DOL 8. She was transitioned to breast milk and tolerated full-volume feeds by DOL 25 without re-accumulation of chylous pleural fluid. She was discharged on DOL 60 and had no readmissions through 1 year of age. At the time of data collection, the patient was 6 years old and was followed and treated for reactive airway disease (RAD).
| Case 2
A male infant delivered by emergency cesarean section at 30 1/7 weeks GA and BW of 2320 g was diagnosed prenatally with fetal hydrops and left-sided pulmonary sequestration at 18 weeks of gestation. Prior to delivery, prenatal pleurocentesis was performed on 4 separate occasions. A cesarean section was planned for the day of delivery following additional pleurocentesis; however, this was converted to emergent cesarean following fetal cardiac decelerations.
Neonatal resuscitation included intubation, chest compressions, line placement, fluid boluses, epinephrine, and placement of a pleural angiocatheter. Following transfer to the neonatal intensive care unit (NICU), bilateral pigtail catheters were placed and 35-160 mL of fluid/ chest tube/day (15-69 mL/kg/tube/d) was drained. Fifty percentage of the volume lost by chest tubes was replaced using 5% albumin or blood products. He was not fed orally but did receive total parental nutrition (TPN). The infant died on DOL 3 after a pulmonary hypertensive crisis that did not respond to treatment with 100% oxygen, highfrequency ventilation, and inhaled nitric oxide. Placental pathology showed acute villous edema and intravillous hemorrhage, possibly due to vascular obstruction, but no clear etiology was identified.
| Case 3
A male infant delivered at 28 3/7 weeks GA and BW of 1350 g by urgent cesarean section because of progressive fetal hydrops, diagnosed at 27 weeks via ultrasound with bilateral pleural effusions and growing concern for fetal well-being. He required resuscitation including airway intubation and chest compressions. Bilateral thoracenteses were performed on DOL 2 and thoracenteses were repeated several times thereafter for re-accumulations of chylous fluid. A right-sided pigtail catheter was placed for a relatively short time from DOL 9-10, during which time chylous fluid drained at 40-100 mL/d (30-74 mL/ kg/d), which was replaced with equal amounts of 5% albumin. He received TPN for the first 14 days of life, and then, oral feeds of longchain fatty acid (LCFA)-free formula were commenced and advanced.
He temporarily tolerated feeds of breast milk from DOL 34-52 but ultimately had to return to formula due to recurrence of chylothorax.
On DOL 69, after having been extubated for nearly 2 months, the infant had a cardiopulmonary arrest and received 2 minutes of chest compressions. The patient was intubated and mechanical ventilation initiated. Inhaled nitric oxide was used for 4 days to treat suspected PH based upon challenges with oxygenation although this was not observed on echocardiogram at that time. A chest X-ray following the event showed stable bilateral pleural effusions, which were later drained via thoracenteses. He was treated with octreotide on DOL 69; however, he developed hematuria on day one of treatment and it was discontinued. Octreotide was restarted on DOL 93 because of persistent chylothoraces and then maintained at 4 lg/kg/h until DOL 116. after successfully transitioning to breast milk. She was too young at the time of data collection for readmission data to be available.
| Analysis of the 5 cases
We present a case series of 5 neonates born between 2009 and 2015 and diagnosed with congenital chylothorax. All had prenatal diagnosis of hydrops fetalis (Table 1) . One infant died at 3 days of life, and the remaining 4 infants were alive at the time of this report. Three of the 5 infants had PH requiring treatment with inhaled nitric oxide. Notably, PH has also been noted as a side effect of octreotide in this population, but octreotide use did not precede PH in any of the infants in this case series. 6 To the authors' knowledge, PH is not often described with chylothoraces. Although pulmonary hypertension can result due to a multitude of factors including prematurity and hypoxia, we hypothesize those infants specifically affected by hydrops fetalis and large CCT are at risk for PH by similar mechanisms to those in congenital diaphragmatic hernia (CDH), which are also not well understood. In CDH, the hypoplastic lung has a small vascular bed and thickened pulmonary arterial walls. It is not clear whether the vascular abnormalities are the etiology or the result of the hypoplastic lung. Although the role of mass effect alone in CDH is also not known, it is, however, interesting to consider how the development of fetal lungs affected by CCT may display similarities.
None of the infants in this case series underwent thoracic duct ligation. Bialkowski et al, similarly, found that of the 28 cases they reviewed, none underwent surgical ligation; Lee et al found that only one in a series of 29 infants had a ligation. 4, 5 In combination with our review, this suggests that nutritional therapy and use of octreotide are most often successful and ligation is therefore infrequently needed. As demonstrated by case 5 mentioned above, medical and nutritional management should be considered even in the setting of very high chyle volume production, in that case over 300 mL/kg/d. This is a notable variation in management from available treatment algorithms for the broad population of children and infants with chylothorax (not specific to CCT), which suggest proceeding to ligation before medical management if the chyle volume is over 100 mL per year of life or over 10 mL/kg after 4 weeks of treatment and also suggest proceeding to surgery if chylothorax persists after 2-4 weeks of medical management. As a somatostatin analog, octreotide inhibits release of growth hormones, glucagon and insulin.
Therefore, infants receiving octreotide must be closely monitored for alterations in blood glucose. Octreotide also causes vasoconstriction of splanchnic vessels and so there is a logical concern about the risk of necrotizing enterocolitis (NEC), which premature neonates are already at risk for. Fortunately, the incidence of NEC among neonates receiving octreotide has not been found to be different from that of the general neonatal population. 7 Of the 4 surviving infants in this series, 3 received octreotide; in 2 cases, the dose was gradually increased to a continuous infusion of 10 lg/kg/h without significant side effects noted. Length of medical treatment with octreotide ranged 3-5 weeks. This difference in practice between infants with CCT and the broader pediatric population with chylothorax may be because CCT patients are often born prematurely (in this series at GA 28 3/7-33 5/7 weeks) and the desire to avoid surgery due to their small size and a difficult-to-visualize thoracic duct. 8 Also unique to this population, most have undergone resuscitation after delivery and associated diagnoses are often yet to be made. A surgical case series has documented that 6 of 14 infants with CCT underwent thoracoscopic parietal pleural clipping, which was performed because visualization of the thoracic duct was not possible. Of the other 8 infants, 4 died and 4 had CCT resolved with medical management.
In that series, 5 of 9 infants who received octreotide later underwent surgery. Of note, the authors of this series cite leukopenia and infection risk as a significant cause of morbidity and mortality in this population but do not report on immunoglobulin levels or prophylactic measures. 8 In our case series, we found that by monitoring of immunoglobulin levels and treatment with both IVIG and prophylactic antibiotics, we were able to mitigate this risk while allowing for a longer period of medical management. The authors, however, have not found prior accounts of coagulopathy as developed in 2 of our patients. We propose that in these 2 patients, protein deficiency interfered with coagulation factor and fibrinogen synthesis. However, this study was not designed, and we do not have enough data, to suggest why some CCT patients develop hypercoagulability and some coagulopathy.
The small number of patients limits our study, and because it is a retrospective case series, patients were not randomized for types of management and results are subject to bias. Information was obtained by chart review and subject to error. It is, however, unlikely and these patients can transition to breast milk after resolution of CCT; therefore, mothers who desire to breastfeed should be supported in collecting and saving breast milk. Octreotide can be safely used in neonates with CCT. We found success by gradually increasing the dose to a maximum continuous infusion rate of 10 lg/kg/h and then weaning the dose prior to discontinuation. Our study demonstrates that octreotide is an important therapeutic approach in CCT even in the setting of chyle volume outputs greater than prior proposed thresholds for surgery.
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